HIV Archives – Page 11 of 90 – Treatment Action Group

TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies

June 3, 2021
Dorrit Walsh

The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.

ACT NOW: END AIDS

May 11, 2021
Dorrit Walsh

ACT NOW: END AIDS (ANEA) is a national coalition of community-based organizations, health departments, national policy partners, and activists committed to ending the HIV epidemic in the United States. TAG is proud to be a co-founder and facilitator for ANEA.

Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs

May 10, 2021
Dorrit Walsh

The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access

May 6, 2021
Dorrit Walsh

Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.

TAG Comments on NIST’s Proposed Rulemaking Changes

April 4, 2021
Dorrit Walsh

TAG submitted comments in response to the National Institute of Standards and Technology's (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically important to public health and the right to science.

Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics

April 1, 2021
Dorrit Walsh

TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.

How Lessons Learned from the HIV Epidemic Can Inform Efforts to Address the COVID-19 Pandemic Through a Racial Equity Lens

March 5, 2021
Dorrit Walsh

Join us on March 15, 2021 at 4:00 p.m. EST for this free webinar, which will discuss a variety of issues concerning disenfranchised communities being disproportionately affected by COVID-19.

Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs

February 25, 2021
Dorrit Walsh

February 25, 2021 — TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and…

Image for the 2021 Community HIV Cure Research Workshop

Pre- and Post-CROI Community HIV Cure Research Workshop

February 17, 2021
Dorrit Walsh

The 2021 Community HIV Cure Research Workshop will take place virtually this year due to the ongoing COVID-19 pandemic. The workshop sessions will be held on Thursday, March 4 and Friday, March 5, 2021 (right before CROI 2021), and then on Tuesday, March 16, 2021 (after the conference).

TAG/COVID-19 Prevention Network: HIV, COVID-19 Outcomes and Implications for COVID-19 Vaccines

January 26, 2021
Dorrit Walsh

Join TAG and COVID-19 Prevention Network (CoVPN) On Tuesday February 2nd at 4pm ET / 1pm PT, at a webinar for community advocates on COVID-19 outcomes in people living with HIV and implications for COVID-19 vaccines.